Format
Sort by

Send to:

Choose Destination

Results: 2

1.

Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

Perazzo H, Pais R, Munteanu M, Ngo Y, Monneret D, Imbert-Bismut F, Moussalli J, Lebray P, Benhamou Y, Thabut D, Ratziu V, de Ledhingen V, Poynard T; FibroFrance Group; EPIC3 Group.

Clin Res Hepatol Gastroenterol. 2014 Sep;38(4):432-9. doi: 10.1016/j.clinre.2014.04.006. Epub 2014 Jun 9.

PMID:
24924901
2.

Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Le Naour G, Vaillant JC, Ratziu V, Charlotte F; Fibrosis-TAGS group.

J Hepatol. 2012 Mar;56(3):541-8. doi: 10.1016/j.jhep.2011.08.007. Epub 2011 Sep 1.

PMID:
21889468

Supplemental Content

Loading ...
Write to the Help Desk